Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor

Anna Pasetto, Alena Gros, Paul F. Robbins, Drew C. Deniger, Todd D. Prickett, Rodrigo Matus-Nicodemos, Daniel C. Douek, Bryan Howie, Harlan Robins, Maria R. Parkhurst, Jared Gartner, Katarzyna Trebska-McGowan, Jessica S. Crystal, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

AdoptivetransferofTcellswithengineeredT-cellreceptor(TCR) genes that target tumor-specific antigens can mediate cancer regression.Accumulatingevidencesuggeststhattheclinicalsuccess ofmanyimmunotherapiesismediatedbyTcellstargetingmutated neoantigens unique to the patient. We hypothesized that the most frequent TCR clonotypes infiltrating the tumor were reactive against tumor antigens. To test this hypothesis, we developed a multistep strategy that involved TCRB deep sequencing of the CD8PD-1 T-cell subset, matching of TCRA-TCRB pairs by pairSEQ and single-cell RT-PCR, followed by testing of the TCRs for tumor-antigen specificity. Analysis of 12 fresh metastatic melanomas revealed that in 11 samples, up to 5 tumor-reactive TCRs were present in the 5 most frequently occurring clonotypes, which included reactivity against neoantigens. These data show the feasibility of developing a rapid, personalized TCR-gene therapy approach that targets the unique set of antigens presented by the autologous tumor without the need to identify their immunologic reactivity.

Original languageEnglish (US)
Pages (from-to)734-743
Number of pages10
JournalCancer immunology research
Volume4
Issue number9
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

T-Cell Antigen Receptor
Neoplasm Antigens
Neoplasms
High-Throughput Nucleotide Sequencing
Autoantigens
T-Lymphocyte Subsets
Genetic Therapy
Melanoma
Polymerase Chain Reaction
Genes

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Pasetto, A., Gros, A., Robbins, P. F., Deniger, D. C., Prickett, T. D., Matus-Nicodemos, R., ... Rosenberg, S. A. (2016). Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. Cancer immunology research, 4(9), 734-743. https://doi.org/10.1158/2326-6066.CIR-16-0001

Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. / Pasetto, Anna; Gros, Alena; Robbins, Paul F.; Deniger, Drew C.; Prickett, Todd D.; Matus-Nicodemos, Rodrigo; Douek, Daniel C.; Howie, Bryan; Robins, Harlan; Parkhurst, Maria R.; Gartner, Jared; Trebska-McGowan, Katarzyna; Crystal, Jessica S.; Rosenberg, Steven A.

In: Cancer immunology research, Vol. 4, No. 9, 01.09.2016, p. 734-743.

Research output: Contribution to journalArticle

Pasetto, A, Gros, A, Robbins, PF, Deniger, DC, Prickett, TD, Matus-Nicodemos, R, Douek, DC, Howie, B, Robins, H, Parkhurst, MR, Gartner, J, Trebska-McGowan, K, Crystal, JS & Rosenberg, SA 2016, 'Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor', Cancer immunology research, vol. 4, no. 9, pp. 734-743. https://doi.org/10.1158/2326-6066.CIR-16-0001
Pasetto, Anna ; Gros, Alena ; Robbins, Paul F. ; Deniger, Drew C. ; Prickett, Todd D. ; Matus-Nicodemos, Rodrigo ; Douek, Daniel C. ; Howie, Bryan ; Robins, Harlan ; Parkhurst, Maria R. ; Gartner, Jared ; Trebska-McGowan, Katarzyna ; Crystal, Jessica S. ; Rosenberg, Steven A. / Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. In: Cancer immunology research. 2016 ; Vol. 4, No. 9. pp. 734-743.
@article{d2b45f1ce1804480b075f3ffdd9dfc55,
title = "Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor",
abstract = "AdoptivetransferofTcellswithengineeredT-cellreceptor(TCR) genes that target tumor-specific antigens can mediate cancer regression.Accumulatingevidencesuggeststhattheclinicalsuccess ofmanyimmunotherapiesismediatedbyTcellstargetingmutated neoantigens unique to the patient. We hypothesized that the most frequent TCR clonotypes infiltrating the tumor were reactive against tumor antigens. To test this hypothesis, we developed a multistep strategy that involved TCRB deep sequencing of the CD8PD-1 T-cell subset, matching of TCRA-TCRB pairs by pairSEQ and single-cell RT-PCR, followed by testing of the TCRs for tumor-antigen specificity. Analysis of 12 fresh metastatic melanomas revealed that in 11 samples, up to 5 tumor-reactive TCRs were present in the 5 most frequently occurring clonotypes, which included reactivity against neoantigens. These data show the feasibility of developing a rapid, personalized TCR-gene therapy approach that targets the unique set of antigens presented by the autologous tumor without the need to identify their immunologic reactivity.",
author = "Anna Pasetto and Alena Gros and Robbins, {Paul F.} and Deniger, {Drew C.} and Prickett, {Todd D.} and Rodrigo Matus-Nicodemos and Douek, {Daniel C.} and Bryan Howie and Harlan Robins and Parkhurst, {Maria R.} and Jared Gartner and Katarzyna Trebska-McGowan and Crystal, {Jessica S.} and Rosenberg, {Steven A.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1158/2326-6066.CIR-16-0001",
language = "English (US)",
volume = "4",
pages = "734--743",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor

AU - Pasetto, Anna

AU - Gros, Alena

AU - Robbins, Paul F.

AU - Deniger, Drew C.

AU - Prickett, Todd D.

AU - Matus-Nicodemos, Rodrigo

AU - Douek, Daniel C.

AU - Howie, Bryan

AU - Robins, Harlan

AU - Parkhurst, Maria R.

AU - Gartner, Jared

AU - Trebska-McGowan, Katarzyna

AU - Crystal, Jessica S.

AU - Rosenberg, Steven A.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - AdoptivetransferofTcellswithengineeredT-cellreceptor(TCR) genes that target tumor-specific antigens can mediate cancer regression.Accumulatingevidencesuggeststhattheclinicalsuccess ofmanyimmunotherapiesismediatedbyTcellstargetingmutated neoantigens unique to the patient. We hypothesized that the most frequent TCR clonotypes infiltrating the tumor were reactive against tumor antigens. To test this hypothesis, we developed a multistep strategy that involved TCRB deep sequencing of the CD8PD-1 T-cell subset, matching of TCRA-TCRB pairs by pairSEQ and single-cell RT-PCR, followed by testing of the TCRs for tumor-antigen specificity. Analysis of 12 fresh metastatic melanomas revealed that in 11 samples, up to 5 tumor-reactive TCRs were present in the 5 most frequently occurring clonotypes, which included reactivity against neoantigens. These data show the feasibility of developing a rapid, personalized TCR-gene therapy approach that targets the unique set of antigens presented by the autologous tumor without the need to identify their immunologic reactivity.

AB - AdoptivetransferofTcellswithengineeredT-cellreceptor(TCR) genes that target tumor-specific antigens can mediate cancer regression.Accumulatingevidencesuggeststhattheclinicalsuccess ofmanyimmunotherapiesismediatedbyTcellstargetingmutated neoantigens unique to the patient. We hypothesized that the most frequent TCR clonotypes infiltrating the tumor were reactive against tumor antigens. To test this hypothesis, we developed a multistep strategy that involved TCRB deep sequencing of the CD8PD-1 T-cell subset, matching of TCRA-TCRB pairs by pairSEQ and single-cell RT-PCR, followed by testing of the TCRs for tumor-antigen specificity. Analysis of 12 fresh metastatic melanomas revealed that in 11 samples, up to 5 tumor-reactive TCRs were present in the 5 most frequently occurring clonotypes, which included reactivity against neoantigens. These data show the feasibility of developing a rapid, personalized TCR-gene therapy approach that targets the unique set of antigens presented by the autologous tumor without the need to identify their immunologic reactivity.

UR - http://www.scopus.com/inward/record.url?scp=85016143090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016143090&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-16-0001

DO - 10.1158/2326-6066.CIR-16-0001

M3 - Article

VL - 4

SP - 734

EP - 743

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 9

ER -